Aprocitentan
![]()  | |
| Clinical data | |
|---|---|
| Trade names | Tryvio | 
| Other names | ACT-132577 | 
| Routes of administration  | By mouth | 
| Drug class | Antihypertensive | 
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
IUPAC name 
  | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H14Br2N6O4S | 
| Molar mass | 546.19 g·mol−1 | 
| 3D model (JSmol) | |
SMILES 
  | |
InChI 
  | |
Aprocitentan, sold under the brand name Tryvio, is a medication used for the treatment of hypertension (high blood pressure).[1] It is an endothelin receptor antagonist active at both endothelin A and endothelin B receptors.[2] It is developed for resistant hypertension by Idorsia, which sold it to Janssen but purchased the rights back in 2023 for $343 million.[3]
Aprocitentan is an active metabolite of macitentan.[4]
Aprocitentan was approved for medical use in the United States in March 2024.[1]
Medical uses
Aprocitentan is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other drugs.[1]
References
- 1 2 3 4 https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf
 - ↑ Ojha, Utkarsh; Ruddaraju, Sanjay; Sabapathy, Navukkarasu; Ravindran, Varun; Worapongsatitaya, Pitchaya; Haq, Jeesanul; et al. (2022). "Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension". American Journal of Cardiovascular Drugs. 22 (3): 271–285. doi:10.1007/s40256-021-00510-9. PMC 8651502. PMID 34878631.
 - ↑ Deswal, Phalguni (6 September 2023). "Idorsia reacquires aprocitentan rights from Janssen for $343m". Pharmaceutical Technology. Archived from the original on 8 November 2023. Retrieved 8 November 2023.
 - ↑ CID 25099191 from PubChem
 
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
